Text Size

Sub Total : $0.00
Place your mouse over each cart item to see full description.

Chemical Name: Mercaptopurine

Please select Dosage and Quantity
  Product Manufacturer Country Dosage Quantity Price($USD)    
Purinethol  GSK Turkey 50 mg 100 $113.99
Mercaptopurine  Generic Canada 50 mg 100 $337.99
Mercaptopurine  Generic India 50 mg 100 $78.99

Purinethol Information:

Cancer medication Purinethol (Mercaptopurine) is an antimetabolite used to treat certain types of cancer. Purinethol (Mercaptopurine) cancer medication may also be used to treat other conditions as determined by your doctor.

Purinethol Side Effects:

Purinethol (Mercaptopurine) side effects, that may go away during Purinethol (Mercaptopurine) cancer medication treatment, include darkening of skin or mild diarrhea. If Purinethol (Mercaptopurine) side effects continue or are bothersome, check with your doctor. CHECK WITH YOUR DOCTOR AS SOON AS POSSIBLE if you experience Purinethol (Mercaptopurine) side effects like skin rash; unusual bruising or bleeding; yellow discoloration of the skin or eyes; abdominal pain or swelling; continuing or severe diarrhea; vomiting; swelling of the feet or legs; fever or chills; cough; or sore throat. If you notice other Purinethol (Mercaptopurine) side effects not listed above, contact your doctor, nurse, or pharmacist.

Indications And Clinical Uses: For remission induction, remission consolidation, and maintenance therapy of the acute leukemias. The response to this agent depends upon the particular sub-classification of the acute leukemia (lymphatic, myelogenous, undifferentiated) and the age of the patient (child or adult). Purinethol (Mercaptopurine) is also indicated for the palliative treatment of chronic myelogenous (granulocytic) leukemia.

Acute Lymphatic (Lymphocytic, Lymphoblastic) Leukemia: Acute lymphatic leukemia occurring in children responds, in general, more favorably to Purinethol (Mercaptopurine) than the same disorder occurring in adults. Given as a single agent for remission induction, Purinethol (Mercaptopurine) induces complete remission in approximately 25% of children and 10% of adults. These results can be improved upon considerably by using multiple, carefully selected agents in combination. Reliance upon Purinethol (Mercaptopurine) alone is seldom justified. The duration of complete remission induced in children with acute lymphatic leukemia is so brief without the use of maintenance therapy that some form of drug therapy is considered essential following remission induction. Purinethol (Mercaptopurine), as a single agent, is capable of significantly prolonging complete remission duration in children; however, combination therapy with multiple agents has produced results superior to that achieved with mercaptopurine alone. The effectiveness of Purinethol (Mercaptopurine) in maintenance programs in adult acute lymphatic leukemia has not been established.

Acute Myelogenous (and Acute Myelomonocytic) Leukemia: As a single agent, Purinethol (Mercaptopurine) will induce complete remission in approximately 10% of children and adults with acute myelogenous leukemia or its sub-classifications. These results are inferior to those achieved with combination chemotherapy employing optimum treatment schedules.

Chronic Myelogenous (Granulocytic) Leukemia: Purinethol (Mercaptopurine) is 1 of several agents with demonstrated efficacy in the treatment of chronic myelogenous leukemia. Approximately 30 to 50% of patients with chronic myelogenous leukemia obtain an objective response to Purinethol (Mercaptopurine). This is less than the 90% objective responses with busulfan, and, of these two agents, busulfan is usually regarded as the preferred drug for initial therapy. CNS Leukemia: Purinethol (Mercaptopurine) is not effective for prophylaxis or treatment of CNS leukemia. Other Neoplasms: Purinethol (Mercaptopurine) is not effective in chronic lymphatic leukemia, the lymphomas (including Hodgkin's Disease), or solid tumors. Contra-Indications: Purinethol (Mercaptopurine) should not be used unless a diagnosis of acute leukemia or chronic myelogenous leukemia has been adequately established and the responsible physician is knowledgeable in assessing response to chemotherapy. Purinethol (Mercaptopurine) should not be used in patients whose disease has demonstrated prior resistance to this drug. In animals and man there is usually complete cross-resistance betweenPurinethol (Mercaptopurine) and thioguanine.

The generic alternative is not manufactured by the company that makes the brand product.

All prices are in US dollars.

The content on this page has been supplied to MediSave.ca by an independent third party contracted to provide information for our website. MediSave.ca relies on these third parties to create and maintain this information and cannot guarantee the medical efficacy, accuracy or reliability of the information that has been provided to us. If you require any advice or information about the drugs on this page, a medical condition or treatment advice, you should always speak to a health professional. Please note that not all products, including any referenced in this page, are shipped by our affiliated Canadian Pharmacy. We affiliate with other dispensaries that ship product to our customers from the following jurisdictions: Canada, Singapore, New Zealand, Turkey, Mauritius, India, and United Kingdom. The items in your order maybe shipped from any of the above jurisdictions. The products are sourced from various countries as well as those listed above. Rest assured, we only affiliate with our authorized dispensaries that procure product through reliable sources.

Back to Main Drug Information Page